153 citations
,
June 2015 in “GenomeBiology.com” The environment around the time of conception can change the VTRNA2-1 gene in a way that lasts for years and may affect disease risk.
January 2026 in “Journal of Sexual and Mental Health” New male contraceptive pills show promise in reducing sperm production with mild side effects.
July 2024 in “Reactions Weekly” 
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
25 citations
,
October 2018 in “Journal of Mind and Medical Sciences” New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
January 2006 in “Xibei zhiwu xuebao” Norethindrone and levonorgestrel can enhance or inhibit root growth in Arabidopsis thaliana depending on the concentration.
7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
February 1978 in “PubMed” Some birth control pills can cause temporary or more serious hair loss.
42 citations
,
May 2009 in “Contraception” The oral contraceptive with ethinyl estradiol and chlormadinone acetate is effective in treating moderate acne.
2 citations
,
June 2020 in “BMC Health Services Research” Health warnings and public health actions led to a significant drop in flutamide prescriptions for women, but off-label use still continues.
25 citations
,
December 2017 in “The Journal of Clinical Endocrinology & Metabolism” Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
November 2024 in “International Journal of Scientific Reports” Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.
24 citations
,
November 1978 in “JAMA” Valproic acid is effective for various seizures, but may cause temporary side effects like drowsiness and stomach issues.
1 citations
,
January 2024 in “BioMed research international” October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.
Covid-19 vaccination during pregnancy is safe for mothers and babies.
14 citations
,
November 2024 in “Pharmaceuticals” Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.
16 citations
,
March 1986 in “Biochemical Pharmacology” 
6 citations
,
June 2013 in “Toxicological Research” Topical Valproate is safe for human skin and unlikely to cause irritation.
6 citations
,
August 2021 in “International Journal of Pharmaceutics” A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” The new drug delivery system improves exemestane's absorption and effectiveness.
2 citations
,
October 2002 in “American Journal of Nursing” Taking the same medication under different brand names caused harmful side effects.
November 2025 in “Yemeni Journal For Medical Sciences” Many women using contraception in Mukalla, Yemen, experience side effects like hair loss and mood swings, needing personalized care.
September 2018 in “Practical diabetes” Sodium valproate is not recommended as a first-line treatment for neuropathy but may be used in resistant cases.
1 citations
,
January 2020 in “Journal of quality in health care & economics” Most Sudanese married women in the study used contraceptives and knew about them, but many didn't know about emergency contraceptives or extra benefits beyond family planning.
March 2019 in “Reactions Weekly” 7 citations
,
October 2023 in “European Journal of Pharmacology” Cannabidivarin (CBDV) may help brain cell growth and survival through the TRPV1 receptor.
April 2026 in “Frontiers in Medicine” A pharmacovigilance study using the FDA Adverse Event Reporting System identified 1,389 cases of cutaneous adverse events (AEs) associated with enfortumab vedotin (EV), a treatment for urothelial carcinoma. Common AEs included rash, pruritus, and alopecia, with severe reactions like Stevens–Johnson syndrome. The study found 44 positive safety signals, 10 of which were previously unlabeled. Most AEs occurred within the first 2 weeks of treatment, primarily in elderly males. Concomitant prednisolone use increased AE reporting and mortality, while amlodipine use decreased AE reporting. These findings underscore the need for early dermatologic surveillance and personalized safety management during EV therapy.